BIIB Share Price Performance
US$168.18
10.17 (6.44%)
4.8% undervalued intrinsic discount
US$176.72
Fair Value
Price US$168.18
AnalystConsensusTarget US$176.72
AnalystLowTarget US$115.00
AnalystHighTarget US$260.00
Fair ValueUS$176.72
Share Pricen/a
Biogen Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 99 Fair Values set on narratives written by author
BIIB Community Narratives
AN
Fair Value US$176.72 4.8% undervalued intrinsic discount
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
1users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
AN
Fair Value US$128 31.4% overvalued intrinsic discount
Rising Drug Pricing Pressures And Generic Competition Will Depress Prospects
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$247.88 32.2% undervalued intrinsic discount
Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Key Takeaways Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure. Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.Read more
1users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
AN
US$176.72
4.8% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-2.43% p.a.
Profit Margin
22.01%
Future PE
15.89x
Share price in 2028
US$218.39
Rising Drug Pricing Pressures And Generic Competition Will Depress Prospects
Key Takeaways Heightened pricing pressures, stricter reimbursement, and payer resistance threaten both revenue growth and the profitability of existing and new therapies. Intensifying competition, shifting innovation trends, and pipeline challenges risk eroding market share, margins, and long-term financial stability.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$128
31.4% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-5.02% p.a.
Profit Margin
19.75%
Future PE
13.89x
Share price in 2028
US$157.27
Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs
Key Takeaways Accelerated adoption of new Alzheimer's and rare disease therapies, aided by diagnostics, advocacy, and expanding guidelines, is poised to drive outsized revenue growth and operating leverage. Strategic partnerships, pipeline innovation, and demographic trends support sustained demand, pipeline expansion, and long-term margin improvement in neurology and rare disease markets.Read more
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$247.88
32.2% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
0.47% p.a.
Profit Margin
32.46%
Future PE
13.82x
Share price in 2028
US$304.56
Recently Updated Narratives
AN
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Fair Value: US$176.72 4.8% undervalued intrinsic discount
56 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Drug Pricing Pressures And Generic Competition Will Depress Prospects
Fair Value: US$128 31.4% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics And Genetic Advances Will Unlock Neurological Breakthroughs
Fair Value: US$247.88 32.2% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biogen Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 10.96
- 76.56%
- 15.98%
- 34.5%
About BIIB
- Founded
- 1978
- Employees
- 7605
- CEO
- WebsiteView website
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
